Clinical Studies

Necrotizing Meningoencephalitis in Pugs (PDE) is a devastating disease. Clinical signs include seizures, circling, cognitive changes, and visual deficits. Our goal is to identify neurological abnormalities in Pugs with high genomic risk for PDE before the onset of the above-mentioned advanced clinical signs.

This clinical trial will evaluate the effectiveness of a novel investigational product for the treatment of oral melanoma in dogs.

Current chemotherapy treatments involve a direct injection into the tumor. We would like to use surgically removed lung tissue to better understand how drugs behave when they are injected into lung tumors in dogs, as well as humans, with lung tumors.

Xylitol is an artificial sweetener commonly found in sugar-free gum. Although safe for humans, xylitol is highly toxic to dogs. This study will compare the liver protective capacity of two veterinary liver protectant products in dogs suffering from xylitol toxicity.

This study seeks to define the rate at which methylnaltrexone (MNTX) is metabolized in dogs following intravenous administration. Postoperative regurgitation is a common side effect of general anesthesia. The opioid-inhibiting effects of MNTX block the risk of opioid-related complications, without reducing pain control and pain management.

This study aims to determine whether or not canine patients diagnosed with canine osteosarcoma (OSA) have intestinal dysbiosis and whether treating intestinal disease improves patient outcomes.

Is your dog undergoing surgery for a ruptured splenic tumor? Ethos Discovery would love to have you and your dog participate in our clinical trial! We are evaluating drugs for the treatment of HSA with the goal of curing this aggressive cancer.

Immune-mediated thrombocytopenia (ITP) is a disorder characterized by severely low platelets due to attack by white blood cells. This is often associated with bruising and occasionally severe bleeding episodes.

A new veterinary device composed of collagen and elastin particles has been developed; it is delivered via intra-articular injection and helps protect cartilage from mechanical grinding. This study seeks to validate this device as a pre-surgical management tool for dogs with cruciate disease.

Proliferating cell nuclear antigen (PCNA) is an important protein necessary for the repair of DNA in cells. Cancer cells express a unique type of PCNA (termed caPCNA) which is only found at small quantities in non-cancer cells.

Verdinexor is a chemotherapy drug that has been conditionally approved by the FDA for the treatment of canine lymphoma. Verdinexor is a selective inhibitor of nuclear export (SINE) compound, and this family of drug has demonstrated encouraging results in preclinical studies when combined with other chemotherapeutic drugs.

This is an exploratory study to evaluate the safety and effectiveness of concomitant intraarticular (IA) and peri-neural (PN) injections of an investigational veterinary product for the control of elbow pain in dogs. This 28-day study also includes a long term follow up at 3 and 6 months.